GlaxoSmithKline has sold two travel vaccines to a Danish biotechnology company for almost €1 billion (US$1.11 billion) as it refocuses on its most profitable and innovative products, reported The Financial Times.
The UK drugmaker announced the decision to relinquish the brands, acquired from rival Novartis in 2015 as part of an asset swap that secured the Swiss company’s vaccines business, “supports GSK’s strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business.”
GSK announced in December that it would split into a standalone pharmaceuticals and vaccines business and a separate consumer health joint venture with Pfizer, giving up on its current diversified corporate model.
On Monday, October 21, it announced the divestment of travel vaccines Rabipur, sold as Rabavert in the US, for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. The Danish company specialises in the research, development, and manufacture of cancer immunotherapies and vaccines for infectious diseases.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Senate Majority Leader Announces Plan for AI Regulation Framework
May 9, 2024 by
CPI
BBVA Initiates Aggressive Takeover Bid for Sabadell
May 9, 2024 by
CPI
TikTok to Label AI-Generated Content Amid Election Interference Concerns
May 9, 2024 by
CPI
Italy’s Antitrust Authority Imposes Heavy Fines on Car Rental Giants
May 9, 2024 by
CPI
Florida Firefighters’ Pension Fund Settles Lawsuit Against Carl Icahn for $2.2 Million
May 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI